Fabtech Technologies IPO Day 2 GMP & Subscription Status: The Fabtech Technologies IPO details are grabbing attention this week as bidding enters its second day. With a price band of ₹181–₹191 per share and a Fabtech Technologies IPO day 2 GMP of ₹20, investors are keenly watching how the issue progresses. On Day 2 morning, subscription numbers indicate modest demand across categories, but the real test will come as institutional buyers step in before the close on October 1, 2025. Let us explore the key highlights, subscription trends, and whether retail investors should consider applying.
Fabtech Technologies IPO Day 2: GMP and Market Sentiment
According to market observers, the Fabtech Technologies IPO latest GMP stands around ₹20 per share. This suggests that investors in the grey market expect a listing at around ₹211, if demand sustains. However, a moderate GMP does not guarantee strong listing gains—it only reflects short-term sentiment.
For investors, the GMP acts as an indicator, but it should not be the sole deciding factor. Retail investors should also weigh company fundamentals, sector demand, and global biotech opportunities before applying.
Fabtech Technologies IPO Day 2 Subscription Status
By the end of Day 1, the IPO had been subscribed 0.70 times. On Day 2 (30 September 2025, 10:12 AM), overall subscription rose slightly to 0.74 times.
Day 2 (Morning) Subscription Breakdown:
- Qualified Institutional Buyers (QIBs): 0.77 times
- Non-Institutional Investors (NIIs): 0.52 times
- Retail Investors: 0.80 times
- Employees: 0.62 times
The QIB category remains steady at 0.77 times, while retail participation has picked up slightly. This gradual rise signals cautious optimism among investors.
How to Apply for Fabtech Technologies IPO Online
Retail investors can apply easily through their broker’s platform using UPI. The steps are straightforward:
- Login to your broker’s app or website.
- Go to the IPO section and select Fabtech Technologies IPO.
- Enter the lot size (minimum 75 shares) and bid price within ₹181–₹191.
- Provide your UPI ID and confirm funds availability.
- Approve the UPI mandate before 5 PM on 1 October 2025.
- Submit the application and track allotment updates post closure.
Applying early ensures fewer last-minute payment glitches, especially during high demand phases.
Fabtech Technologies IPO: Key Details You Must Know
Fabtech Technologies Limited, incorporated in 2018, operates in the biopharma engineering sector. The company provides turnkey solutions for pharmaceutical, biotechnology, and healthcare industries, covering the full lifecycle of manufacturing—from design to commissioning.
- IPO Open Date: 29 September 2025
- IPO Close Date: 1 October 2025
- Issue Type: Book Built Issue
- Price Band: ₹181 – ₹191 per equity share
- Lot Size: 75 shares
- Total Issue Size: ₹230.35 crore (fresh issue only)
- Employee Discount: ₹9 per equity share
- Intended Use of Proceeds: Working capital needs, acquisitions, and general corporate purposes
The company already has a global footprint in over 60 countries, including the USA, Turkey, UAE, Egypt, South Africa, and India. With 185 permanent employees, Fabtech offers expertise beyond pharma—serving industries like food & beverages, IT hardware, semiconductors, and aeronautics.
Should You Apply for Fabtech IPO?
The IPO comes from a niche engineering firm with strong global exposure and diversified industry presence. The company’s expertise in cleanroom technology, HVAC systems, and pharma process equipment positions it well in the growing biotech and healthcare infrastructure market.
However, subscription data so far suggests demand is lukewarm, especially from NIIs. Investors must watch QIB participation on the final day since institutional backing often determines listing success.
If you are a retail investor with a medium-term horizon, Fabtech may be worth considering, given its reasonable price band and sectoral growth. But for those seeking quick listing gains, the current GMP of ₹20 suggests only modest returns.
Final Takeaway
The Fabtech Technologies IPO is showing steady but not aggressive demand in its early days. With strong fundamentals, a global presence, and a focused business model, the company holds promise. Yet, investors should evaluate risk appetite before applying. Keep an eye on final-day subscription, especially from QIBs, to make an informed decision.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
